---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-004880"
form_type: "8-K"
ticker: "ENSC"
cik: "0001716947"
company_name: "Ensysce Biosciences, Inc."
filed_at: "2025-02-04T23:59:59+00:00"
generated_at: "2026-05-27T03:33:33.611178+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Ensysce secures up to $10M R&D funding from Galephar in equity-based development deal

## Summary
- Galephar commits up to $10 million to support R&D, manufacturing, and testing of PF614 and PF614-MPAR.
- Ensysce issues 1% of outstanding shares as restricted stock vesting in thirds based on project milestones.
- Development costs compensated with 50% restricted stock and 50% freely tradeable shares at 1.2x actual cost.
- 15-year term with IP created related to Ensysce's products owned exclusively by Ensysce.
- Share price fixed using trailing five-day closing price; no future variable pricing permitted.

## SEC filing metadata
- accession: 0001493152-25-004880
- form_type: 8-K
- ticker: ENSC
- cik: 0001716947
- company_name: Ensysce Biosciences, Inc.
- filed_at: 2025-02-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716947/000149315225004880/0001493152-25-004880-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716947/000149315225004880/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-004880
- JSON: https://secwatch.observer/filing/0001493152-25-004880.json
- Plain text: https://secwatch.observer/filing/0001493152-25-004880.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.